Calcineurin regulation of cytoskeleton organization: A new paradigm to analyse the effects of calcineurin inhibitors on the kidney

Journal of Cellular and Molecular Medicine

Volumn 16, Issue 2, 2012, Pages 218-227

  Descazeaud, Virginie ^a,b   Mestre, Elodie ^a,b   Marquet, Pierre ^a,b   Essig, Marie ^a,b,c  

^a INSERM   (France)

^b UNIVERSITY OF LIMOGES   (France)

^c LIMOGES UNIVERSITY HOSPITAL   (France)

Author keywords

Calcineurin; Cytoskeleton; Kidney; Nephrotoxicity

Indexed keywords

CALCINEURIN; TRANSCRIPTION FACTOR NFAT;

CARDIOMEGALY; CYTOLOGY; CYTOSKELETON; DRUG ANTAGONISM; HEART; HEART MUSCLE CELL; HUMAN; KIDNEY; METABOLISM; NERVE CELL; PATHOLOGY; PHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION;

CALCINEURIN; CARDIOMEGALY; CYTOSKELETON; HEART; HUMANS; KIDNEY; MYOCYTES, CARDIAC; NEURONS; NFATC TRANSCRIPTION FACTORS; SIGNAL TRANSDUCTION;

EID: 84856362503     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2011.01398.x     Document Type: Review

References (105)

1. Rusnak F, Mertz P. Calcineurin: form and function. Physiol Rev. 2000; 80: 1483-521.
2. 2+ and protein modulator-activated cyclic nucleotide phosphodiesterase. Biochem Biophys Res Commun. 1976; 72: 926-32.
3. Jain J, McCaffrey PG, Miner Z, et al The T-cell transcription factor NFATp is a substrate for calcineurin and interacts with Fos and Jun. Nature. 1993; 365: 352-5.
4. Liu J, Farmer JD Jr, Lane WS, et al Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell. 1991; 66: 807-15.
5. Sugimoto T, Stewart S, Guan KL. The calcium/calmodulin-dependent protein phosphatase calcineurin is the major Elk-1 phosphatase. J Biol Chem. 1997; 272: 29415-8.
6. Liu S, Liu P, Borras A, et al Cyclosporin A-sensitive induction of the Epstein-Barr virus lytic switch is mediated via a novel pathway involving a MEF2 family member. EMBO J. 1997; 16: 143-53.
7. Gaestel M, Benndorf R, Hayess K, et al Dephosphorylation of the small heat shock protein hsp25 by calcium/calmodulin-dependent (type 2B) protein phosphatase. J Biol Chem. 1992; 267: 21607-11.
8. Liu YC, Storm DR. Dephosphorylation of neuromodulin by calcineurin. J Biol Chem. 1989; 264: 12800-4.
9. Lieberman DN, Mody I. Regulation of NMDA channel function by endogenous Ca(2+)-dependent phosphatase. Nature. 1994; 369: 235-9.
10. Goto S, Yamamoto H, Fukunaga K, et al Dephosphorylation of microtubule-associated protein 2, tau factor, and tubulin by calcineurin. J Neurochem. 1985; 45: 276-83.
11. Wang Y, Shibasaki F, Mizuno K. Calcium signal-induced cofilin dephosphorylation is mediated by Slingshot via calcineurin. J Biol Chem. 2005; 280: 12683-9.
12. Faul C, Donnelly M, Merscher-Gomez S, et al The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat Med. 2008; 14: 931-8.
13. Ceglia I, Kim Y, Nairn AC, et al Signaling pathways controlling the phosphorylation state of WAVE1, a regulator of actin polymerization. J Neurochem. 2010; 114: 182-90.
14. Ferreira A, Kincaid R, Kosik KS. Calcineurin is associated with the cytoskeleton of cultured neurons and has a role in the acquisition of polarity. Mol Biol Cell. 1993; 4: 1225-38.
15. Ono T, Yamamoto H, Tashima K, et al Dephosphorylation of abnormal sites of tau factor by protein phosphatases and its implication for Alzheimer's disease. Neurochem Int. 1995; 26: 205-15.
16. Rahman A, Grundke-Iqbal I, Iqbal K. PP2B isolated from human brain preferentially dephosphorylates Ser-262 and Ser-396 of the Alzheimer disease abnormally hyperphosphorylated tau. J Neural Transm. 2006; 113: 219-30.
17. Fiumelli H, Riederer IM, Martin JL, et al Phosphorylation of neurofilament subunit NF-M is regulated by activation of NMDA receptors and modulates cytoskeleton stability and neuronal shape. Cell Motil Cytoskeleton. 2008; 65: 495-504.
18. Tanaka T, Takeda M, Niigawa H, et al Phosphorylated neurofilament accumulation in neuronal perikarya by cyclosporin A injection in rat brain. Methods Find Exp Clin Pharmacol. 1993; 15: 77-87.
19. Kayyali US, Zhang W, Yee AG, et al Cytoskeletal changes in the brains of mice lacking calcineurin A alpha. J Neurochem. 1997; 68: 1668-78.
20. Letourneau PC. The cytoskeleton in nerve growth cone motility and axonal pathfinding. Perspect Dev Neurobiol. 1996; 4: 111-23.
21. Chang HY, Takei K, Sydor AM, et al Asymmetric retraction of growth cone filopodia following focal inactivation of calcineurin. Nature. 1995; 376: 686-90.
22. Lautermilch NJ, Spitzer NC. Regulation of calcineurin by growth cone calcium waves controls neurite extension. J Neurosci. 2000; 20: 315-25.
23. Polli JW, Billingsley ML, Kincaid RL. Expression of the calmodulin-dependent protein phosphatase, calcineurin, in rat brain: developmental patterns and the role of nigrostriatal innervation. Brain Res Dev Brain Res. 1991; 63: 105-19.
24. Karliner JS, Kagiya T, Simpson PC. Effects of pertussis toxin on alpha 1-agonist-mediated phosphatidylinositide turnover and myocardial cell hypertrophy in neonatal rat ventricular myocytes. Experientia. 1990; 46: 81-4.
25. Leite MF, Page E, Ambler SK. Regulation of ANP secretion by endothelin-1 in cultured atrial myocytes: desensitization and receptor subtype. Am J Physiol. 1994; 267: H2193-203.
26. Sadoshima J, Izumo S. Signal transduction pathways of angiotensin II-induced c-fos gene expression in cardiac myocytes in vitro. Roles of phospholipid-derived second messengers. Circ Res. 1993; 73: 424-38.
27. Perreault CL, Shannon RP, Shen YT, et al Excitation-contraction coupling in isolated myocardium from dogs with compensated left ventricular hypertrophy. Am J Physiol. 1994; 266: H2436-42.
28. Saeki Y, Kurihara S, Hongo K, et al Tension and intracellular calcium transients of activated ferret ventricular muscle in response to step length changes. Adv Exp Med Biol. 1993; 332: 639-47; discussion 47-8.
29. Samuel JL, Bertier B, Bugaisky L, et al Different distributions of microtubules, desmin filaments and isomyosins during the onset of cardiac hypertrophy in the rat. Eur J Cell Biol. 1984; 34: 300-6.
30. Samuel JL, Marotte F, Delcayre C, et al Microtubule reorganization is related to rate of heart myocyte hypertrophy in rat. Am J Physiol. 1986; 251: H1118-25.
31. Ishibashi Y, Tsutsui H, Yamamoto S, et al Role of microtubules in myocyte contractile dysfunction during cardiac hypertrophy in the rat. Am J Physiol. 1996; 271: H1978-87.
32. Tsutsui H, Ishihara K, Cooper Gt. Cytoskeletal role in the contractile dysfunction of hypertrophied myocardium. Science. 1993; 260: 682-7.
33. Tsutsui H, Tagawa H, Kent RL, et al Role of microtubules in contractile dysfunction of hypertrophied cardiocytes. Circulation. 1994; 90: 533-55.
34. Tagawa H, Rozich JD, Tsutsui H, et al Basis for increased microtubules in pressure-hypertrophied cardiocytes. Circulation. 1996; 93: 1230-43.
35. Narishige T, Blade KL, Ishibashi Y, et al Cardiac hypertrophic and developmental regulation of the beta-tubulin multigene family. J Biol Chem. 1999; 274: 9692-7.
36. Sato H, Nagai T, Kuppuswamy D, et al Microtubule stabilization in pressure overload cardiac hypertrophy. J Cell Biol. 1997; 139: 963-73.
37. Carlyle WC, Toher CA, Vandervelde JR, et al Changes in beta-actin mRNA expression in remodeling canine myocardium. J Mol Cell Cardiol. 1996; 28: 53-63.
38. Collins JF, Pawloski-Dahm C, Davis MG, et al The role of the cytoskeleton in left ventricular pressure overload hypertrophy and failure. J Mol Cell Cardiol. 1996; 28: 1435-43.
39. Schaper J, Froede R, Hein S, et al Impairment of the myocardial ultrastructure and changes of the cytoskeleton in dilated cardiomyopathy. Circulation. 1991; 83: 504-14.
40. De Windt LJ, Lim HW, Bueno OF, et al Targeted inhibition of calcineurin attenuates cardiac hypertrophy in vivo. Proc Natl Acad Sci USA. 2001; 98: 3322-7.
41. Eto Y, Yonekura K, Sonoda M, et al Calcineurin is activated in rat hearts with physiological left ventricular hypertrophy induced by voluntary exercise training. Circulation. 2000; 101: 2134-7.
42. Kamiya H, Okumura K, Ito M, et al Calcineurin inhibitor attenuates cardiac hypertrophy due to energy metabolic disorder. Can J Cardiol. 2001; 17: 1292-8.
43. Li J, Yatani A, Kim SJ, et al Neurally-mediated increase in calcineurin activity regulates cardiac contractile function in absence of hypertrophy. Cardiovasc Res. 2003; 59: 649-57.
44. Lim HW, De Windt LJ, Mante J, et al Reversal of cardiac hypertrophy in transgenic disease models by calcineurin inhibition. J Mol Cell Cardiol. 2000; 32: 697-709.
45. Lim HW, De Windt LJ, Steinberg L, et al Calcineurin expression, activation, and function in cardiac pressure-overload hypertrophy. Circulation. 2000; 101: 2431-7.
46. Nagata K, Somura F, Obata K, et al AT1 receptor blockade reduces cardiac calcineurin activity in hypertensive rats. Hypertension. 2002; 40: 168-74.
47. Saito T, Fukuzawa J, Osaki J, et al Roles of calcineurin and calcium/calmodulin-dependent protein kinase II in pressure overload-induced cardiac hypertrophy. J Mol Cell Cardiol. 2003; 35: 1153-60.
48. Shimoyama M, Hayashi D, Takimoto E, et al Calcineurin plays a critical role in pressure overload-induced cardiac hypertrophy. Circulation. 1999; 100: 2449-54.
49. Shimoyama M, Hayashi D, Zou Y, et al Calcineurin inhibitor attenuates the development and induces the regression of cardiac hypertrophy in rats with salt-sensitive hypertension. J Cardiol. 2001; 37: 114-8.
50. Sussman MA, Lim HW, Gude N, et al Prevention of cardiac hypertrophy in mice by calcineurin inhibition. Science. 1998; 281: 1690-3.
51. Takeda Y, Yoneda T, Demura M, et al Calcineurin inhibition attenuates mineralocorticoid-induced cardiac hypertrophy. Circulation. 2002; 105: 677-9.
52. Zou Y, Hiroi Y, Uozumi H, et al Calcineurin plays a critical role in the development of pressure overload-induced cardiac hypertrophy. Circulation. 2001; 104: 97-101.
53. Haq S, Choukroun G, Lim H, et al Differential activation of signal transduction pathways in human hearts with hypertrophy versus advanced heart failure. Circulation. 2001; 103: 670-7.
54. Lim HW, Molkentin JD. Calcineurin and human heart failure. Nat Med. 1999; 5: 246-7.
55. Ritter O, Hack S, Schuh K, et al Calcineurin in human heart hypertrophy. Circulation. 2002; 105: 2265-9.
56. Molkentin JD, Lu JR, Antos CL, et al A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell. 1998; 93: 215-28.
57. De Windt LJ, Lim HW, Taigen T, et al Calcineurin-mediated hypertrophy protects cardiomyocytes from apoptosis in vitro and in vivo: an apoptosis-independent model of dilated heart failure. Circ Res. 2000; 86: 255-63.
58. Deng L, Huang B, Qin D, et al Calcineurin inhibition ameliorates structural, contractile, and electrophysiologic consequences of postinfarction remodeling. J Cardiovasc Electrophysiol. 2001; 12: 1055-61.
59. Goldspink PH, McKinney RD, Kimball VA, et al Angiotensin II induced cardiac hypertrophy in vivo is inhibited by cyclosporin A in adult rats. Mol Cell Biochem. 2001; 226: 83-8.
60. Hill JA, Karimi M, Kutschke W, et al Cardiac hypertrophy is not a required compensatory response to short-term pressure overload. Circulation. 2000; 101: 2863-9.
61. Jordan MC, Quednau BD, Roos KP, et al Cyclosporin A regulates sodium-calcium exchanger (NCX1) gene expression in vitro and cardiac hypertrophy in NCX1 transgenic mice. Ann N Y Acad Sci. 2002; 976: 259-67.
62. Meguro T, Hong C, Asai K, et al Cyclosporine attenuates pressure-overload hypertrophy in mice while enhancing susceptibility to decompensation and heart failure. Circ Res. 1999; 84: 735-40.
63. Mende U, Kagen A, Cohen A, et al Transient cardiac expression of constitutively active Galphaq leads to hypertrophy and dilated cardiomyopathy by calcineurin-dependent and independent pathways. Proc Natl Acad Sci USA. 1998; 95: 13893-8.
64. Mervaala E, Muller DN, Park JK, et al Cyclosporin A protects against angiotensin II-induced end-organ damage in double transgenic rats harboring human renin and angiotensinogen genes. Hypertension. 2000; 35: 360-6.
65. Murat A, Pellieux C, Brunner HR, et al Calcineurin blockade prevents cardiac mitogen-activated protein kinase activation and hypertrophy in renovascular hypertension. J Biol Chem. 2000; 275: 40867-73.
66. Oie E, Bjornerheim R, Clausen OP, et al Cyclosporin A inhibits cardiac hypertrophy and enhances cardiac dysfunction during postinfarction failure in rats. Am J Physiol Heart Circ Physiol. 2000; 278: H2115-23.
67. Sakata Y, Masuyama T, Yamamoto K, et al Calcineurin inhibitor attenuates left ventricular hypertrophy, leading to prevention of heart failure in hypertensive rats. Circulation. 2000; 102: 2269-75.
68. Shimoyama M, Hayashi D, Zou Y, et al Calcineurin inhibitor attenuates the development and induces the regression of cardiac hypertrophy in rats with salt-sensitive hypertension. Circulation. 2000; 102: 1996-2004.
69. 2+ exchanger remodeling in pressure overload cardiac hypertrophy. J Biol Chem. 2001; 276: 17706-11.
70. Taigen T, De Windt LJ, Lim HW, et al Targeted inhibition of calcineurin prevents agonist-induced cardiomyocyte hypertrophy. Proc Natl Acad Sci USA. 2000; 97: 1196-201.
71. Rothermel BA, McKinsey TA, Vega RB, et al Myocyte-enriched calcineurin-interacting protein, MCIP1, inhibits cardiac hypertrophy in vivo. Proc Natl Acad Sci USA. 2001; 98: 3328-33.
72. Bueno OF, Wilkins BJ, Tymitz KM, et al Impaired cardiac hypertrophic response in Calcineurin Abeta-deficient mice. Proc Natl Acad Sci USA. 2002; 99: 4586-91.
73. Graef IA, Gastier JM, Francke U, et al Evolutionary relationships among Rel domains indicate functional diversification by recombination. Proc Natl Acad Sci USA. 2001; 98: 5740-5.
74. Graef IA, Wang F, Charron F, et al Neurotrophins and netrins require calcineurin/NFAT signaling to stimulate outgrowth of embryonic axons. Cell. 2003; 113: 657-70.
75. Yoshida T, Mishina M. Distinct roles of calcineurin-nuclear factor of activated T-cells and protein kinase A-cAMP response element-binding protein signaling in presynaptic differentiation. J Neurosci. 2005; 25: 3067-79.
76. Nguyen T, Lindner R, Tedeschi A, et al NFAT-3 is a transcriptional repressor of the growth-associated protein 43 during neuronal maturation. J Biol Chem. 2009; 284: 18816-23.
77. Wilkins BJ, De Windt LJ, Bueno OF, et al Targeted disruption of NFATc3, but not NFATc4, reveals an intrinsic defect in calcineurin-mediated cardiac hypertrophic growth. Mol Cell Biol. 2002; 22: 7603-13.
78. van Rooij E, Doevendans PA, de Theije CC, et al Requirement of nuclear factor of activated T-cells in calcineurin-mediated cardiomyocyte hypertrophy. J Biol Chem. 2002; 277: 48617-26.
79. Haq S, Choukroun G, Kang ZB, et al Glycogen synthase kinase-3beta is a negative regulator of cardiomyocyte hypertrophy. J Cell Biol. 2000; 151: 117-30.
80. Antos CL, McKinsey TA, Frey N, et al Activated glycogen synthase-3 beta suppresses cardiac hypertrophy in vivo. Proc Natl Acad Sci USA. 2002; 99: 907-12.
81. Ono S. Mechanism of depolymerization and severing of actin filaments and its significance in cytoskeletal dynamics. Int Rev Cytol. 2007; 258: 1-82.
82. Meberg PJ, Ono S, Minamide LS, et al Actin depolymerizing factor and cofilin phosphorylation dynamics: response to signals that regulate neurite extension. Cell Motil Cytoskeleton. 1998; 39: 172-90.
83. Homma K, Niino Y, Hotta K, et al Ca(2+) influx through P2X receptors induces actin cytoskeleton reorganization by the formation of cofilin rods in neurites. Mol Cell Neurosci. 2008; 37: 261-70.
84. Kurz JE, Moore BJ, Henderson SC, et al A cellular mechanism for dendritic spine loss in the pilocarpine model of status epilepticus. Epilepsia. 2008; 49: 1696-710.
85. Pandey D, Goyal P, Dwivedi S, et al Unraveling a novel Rac1-mediated signaling pathway that regulates cofilin dephosphorylation and secretion in thrombin-stimulated platelets. Blood. 2009; 114: 415-24.
86. Zhao R, Du L, Huang Y, et al Actin depolymerization factor/cofilin activation regulates actin polymerization and tension development in canine tracheal smooth muscle. J Biol Chem. 2008; 283: 36522-31.
87. Abdul-Majeed S, Moloney BC, Nauli SM. Mechanisms regulating cilia growth and cilia function in endothelial cells. Cell Mol Life Sci. 2011; doi:
88. Takenawa T, Suetsugu S. The WASP-WAVE protein network: connecting the membrane to the cytoskeleton. Nat Rev Mol Cell Biol. 2007; 8: 37-48.
89. Kim Y, Sung JY, Ceglia I, et al Phosphorylation of WAVE1 regulates actin polymerization and dendritic spine morphology. Nature. 2006; 442: 814-7.
90. Suetsugu S, Yamazaki D, Kurisu S, et al Differential roles of WAVE1 and WAVE2 in dorsal and peripheral ruffle formation for fibroblast cell migration. Dev Cell. 2003; 5: 595-609.
91. Yamazaki D, Suetsugu S, Miki H, et al WAVE2 is required for directed cell migration and cardiovascular development. Nature. 2003; 424: 452-6.
92. Kawamura K, Takano K, Suetsugu S, et al N-WASP and WAVE2 acting downstream of phosphatidylinositol 3-kinase are required for myogenic cell migration induced by hepatocyte growth factor. J Biol Chem. 2004; 279: 54862-71.
93. Yamazaki D, Oikawa T, Takenawa T. Rac-WAVE-mediated actin reorganization is required for organization and maintenance of cell-cell adhesion. J Cell Sci. 2007; 120: 86-100.
94. Huang Y, Burkhardt JK. T-cell-receptor-dependent actin regulatory mechanisms. J Cell Sci. 2007; 120: 723-30.
95. Gooch JL, Toro JJ, Guler RL, et al Calcineurin A-alpha but not A-beta is required for normal kidney development and function. Am J Pathol. 2004; 165: 1755-65.
96. Mundel P, Heid HW, Mundel TM, et al Synaptopodin: an actin-associated protein in telencephalic dendrites and renal podocytes. J Cell Biol. 1997; 139: 193-204.
97. Kobayashi N. Mechanism of the process formation; podocytes versus neurons. Microsc Res Tech. 2002; 57: 217-23.
98. Coward RJ, Foster RR, Patton D, et al Nephrotic plasma alters slit diaphragm-dependent signaling and translocates nephrin, Podocin, and CD2 associated protein in cultured human podocytes. J Am Soc Nephrol. 2005; 16: 629-37.
99. Rico M, Mukherjee A, Konieczkowski M, et al WT1-interacting protein and ZO-1 translocate into podocyte nuclei after puromycin aminonucleoside treatment. Am J Physiol Renal Physiol. 2005; 289: F431-41.
100. Asanuma K, Kim K, Oh J, et al Synaptopodin regulates the actin-bundling activity of alpha-actinin in an isoform-specific manner. J Clin Invest. 2005; 115: 1188-98.
101. Asanuma K, Yanagida-Asanuma E, Faul C, et al Synaptopodin orchestrates actin organization and cell motility via regulation of RhoA signalling. Nat Cell Biol. 2006; 8: 485-91.
102. Schlondorff J, Del Camino D, Carrasquillo R, et al TRPC6 mutations associated with focal segmental glomerulosclerosis cause constitutive activation of NFAT-dependent transcription. Am J Physiol Cell Physiol. 2009; 296: C558-69.
103. Wang Y, Jarad G, Tripathi P, et al Activation of NFAT signaling in podocytes causes glomerulosclerosis. J Am Soc Nephrol. 2010; 21: 1657-66.
104. De Merindol V, Mestre M, Essig M. Cyclosporine-induced modifications of proximal tubule actin organization and tPA expression may contribute to the interstitial fibrosis during chronic allograft dysfunction. 43rd Annual Meeting of the American Society of Nephrology, Denver. J Am Soc Nephrol. 2010; 21: 793A.
105. Essig M, Terzi F, Burtin M, et al Mechanical strains induced by tubular flow affect the phenotype of proximal tubular cells. Am J Physiol Renal Physiol. 2001; 281: F751-62.